Key result
Selective use of mechanical support in high-risk percutaneous coronary intervention (CHIP-BCIS3) yielded neutral results that are considered neither positive nor definitive.
Why the study?
Does elective routine percutaneous mechanical circulatory support improve outcomes in patients undergoing high-risk and complex PCI?
Does elective routine percutaneous mechanical circulatory support improve outcomes in patients undergoing high-risk and complex PCI?
Answers are grounded in this paper and cite their sources.
Routine elective use of percutaneous mechanical circulatory support in high-risk PCI is not currently supported by randomized trial data, though selective use may still be beneficial.
Today, based on CHIP-BCIS3, elective routine percutaneous mechanical circulatory (pMCS) support in high-risk and complex percutaneous coronary intervention (PCI) is not supported. (10.1056/NEJMoa2515704); however, this conclusion should be interpreted with caution in view of the relatively small sample size and the resulting wide confidence intervals, which limit the precision of the estimated treatment effects. High-risk PCI is increasingly performed in patients with complex coronary artery disease (CAD) and impaired left ventricular (LV) function. These patients may derive substantial benefit from revascularisation but are at heightened risk of periprocedural haemodynamic compromise and cardiogenic shock.1–3 Elective pMCS has been proposed to maintain cardiac output, haemodynamic stability and mitigate ischaemia during complex interventions. Early randomized trials using the intra-aortic balloon pump, notably the BCIS-1 trial, did not demonstrate short-term benefit, although a reduction in long-term mortality was observed.4,5 More recently, percutaneous microaxial flow pumps (aAFP), such as the Impella system (Johnson & Johnson MedTech Heart Recovery), have seen increasing use, underpinned by strong physiological rationale and observational data demonstrating improved haemodynamics; notably, the Danish–German Cardiogenic Shock (DANGER-SHOCK) trial showed clinical benefit in a selected population with cardiogenic shock, highlighting the potential of this approach in high-risk settings.6–14 Registry analyses in Impella-supported PCI, however, have produced conflicting results, with some suggesting improved outcomes and others reporting increased complications, including bleeding and stroke.15–17
No takes yet. Share an insight, caveat, or question.
Vranckx et al. (2026) studied this question. Selective use of mechanical support in high-risk percutaneous coronary intervention (CHIP-BCIS3) yielded neutral results that are considered neither positive nor definitive.
Synapse has enriched 10 related papers. Consider them for comparative context: